Biogen Idec and Sweden's Swedish Orphan Biovitrum , or Sobi, said on Friday a Phase 3 trial of its hemophilia treatment in children under 12 met its primary endpoint. The biopharmaceutical companies said this will help them seek marketing approval for the treatment, Alprolix, in Europe. It is already approved for use in children in the U.S. "These data will enable regulatory filings in Europe later this year as well as support pediatric indications in other countries, with the potential to help address a critical need among children with hemophilia B," said Aoife Brennan, an executive of hematology clinical development at Biogen. Biogen's stock, which was still inactive in premarket trade, has run up 34% over the past three months, compared with a 1.8% gain in the S&P 500.
Copyright © 2015 MarketWatch, Inc.